Editorial: Immunotherapy in renal cell carcinoma

Viktor Gruenwald; Walter J Storkus

doi:10.3389/fonc.2022.945510

Editorial: Immunotherapy in renal cell carcinoma

Front Oncol. 2022 Jul 27:12:945510. doi: 10.3389/fonc.2022.945510. eCollection 2022.

Authors

Viktor Gruenwald¹, Walter J Storkus²

Affiliations

¹ Interdisciplinary Genitourinary Oncology, Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany.
² Dermatology, Immunology, Pathology and Bioengineering, University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, United States.

Abstract

This collection contains 10 reports published In Frontiers in Oncology between August 2020 and March 2022 broadly focused on the immunobiology of renal cell carcinoma (RCC), the impact of immunotherapy in the setting of RCC, and the identification of biomarkers that are prognostic of RCC patient outcomes and response to immunotherapy.

Keywords: biomarker; cancer; immunotherapy; renal cell carcinoma (RCC); urologic oncology.

Publication types

Editorial